Bernadette Connaughton Sells 2,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Key Points

• Bernadette Connaughton, a director at Halozyme Therapeutics, sold 2,000 shares at an average price of $75.24, reducing her ownership by 4.26% and leaving her with approximately 44,952 shares valued at about $3.38 million.
• Halozyme Therapeutics reported a strong quarterly earnings performance with $1.54 EPS, surpassing estimates by $0.31, and revenue of $325.72 million, up 40.8% from the previous year.
• The stock price of Halozyme Therapeutics has recently increased by 2.2%, reaching $74.94, with a market capitalization of $8.77 billion and a P/E ratio of 17.15.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $75.24, for a total transaction of $150,480.00. Following the transaction, the director owned 44,952 shares in the company, valued at approximately $3,382,188.48. The trade was a 4.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Bernadette Connaughton also recently made the following trade(s):

• On Tuesday, September 2nd, Bernadette Connaughton sold 4,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $73.68, for a total transaction of $294,720.00.

Halozyme Therapeutics Stock Up 2.2%

Shares of Halozyme Therapeutics stock traded up $1.60 on Wednesday, reaching $74.94. The stock had a trading volume of 4,355,235 shares, compared to its average volume of 2,016,236. The company has a 50 day moving average price of $69.97 and a 200 day moving average price of $61.86. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $79.50. The stock has a market capitalization of $8.77 billion, a P/E ratio of 17.15, a P/E/G ratio of 0.40 and a beta of 1.16.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. During the same quarter in the previous year, the firm earned $0.91 EPS. The company's quarterly revenue was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Institutional Trading of Halozyme Therapeutics

A number of large investors have recently made changes to their positions in the company. Isthmus Partners LLC increased its stake in shares of Halozyme Therapeutics by 2.5% during the first quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company's stock worth $439,000 after buying an additional 169 shares during the period. EverSource Wealth Advisors LLC grew its position in shares of Halozyme Therapeutics by 6.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company's stock worth $140,000 after acquiring an additional 174 shares during the last quarter. OneDigital Investment Advisors LLC grew its position in shares of Halozyme Therapeutics by 1.7% during the first quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company's stock worth $649,000 after acquiring an additional 175 shares during the last quarter. Park Place Capital Corp lifted its holdings in shares of Halozyme Therapeutics by 20.1% during the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock worth $69,000 after purchasing an additional 182 shares during the period. Finally, Xponance Inc. lifted its holdings in shares of Halozyme Therapeutics by 1.1% during the first quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company's stock worth $1,190,000 after purchasing an additional 198 shares during the period. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on HALO. Wall Street Zen cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 5th. Morgan Stanley boosted their price target on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an "overweight" rating in a report on Monday, August 18th. The Goldman Sachs Group assumed coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. They set a "neutral" rating and a $55.00 target price for the company. HC Wainwright upped their target price on shares of Halozyme Therapeutics from $75.00 to $85.00 and gave the stock a "buy" rating in a report on Monday, September 22nd. Finally, Benchmark upped their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a "buy" rating in a report on Wednesday, September 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Halozyme Therapeutics has an average rating of "Hold" and an average price target of $69.89.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.